Company profileNeural interface
Gestala
A newly founded Chinese company pursuing brain interfaces based on ultrasound, without implanted electrodes.
- Location
- Chengdu, China
- Founded
- 2026
- Class
- Neural interfaceNot counted among core BCI companies.
- Funding stage
- Angel+
- Sources last checked
- 4 Oct 2026
What they are building
Launched in January 2026 to combine functional ultrasound imaging, focused ultrasound and AI; its first stated target is chronic pain.
- Interface category
- Focused ultrasound neuromodulation · Functional ultrasound imaging
- Signal
- tFUS: Pulsed low-intensity ultrasoundfUS imaging: Blood-volume changes at depth
- Invasiveness
- Non-invasive
- Recording / stimulation
- Recording and stimulation
- Main use cases
- Restore
Where they are clinically
Preclinical
Bench, animal or cadaver work. No human participants.
No human or animal data have been disclosed.
Access today
Concept
A proposed approach without published human or animal demonstration.
- Shown in people
- Nothing public beyond the company's own statements.
- Still an aim
- Reading and stimulating the brain by ultrasound through the skull, first for chronic pain. A product unveiling is promised for the end of 2026.
- What stands in the way
- Data of any kind: no animal or human results have been disclosed.
On record here: 0 peer-reviewed papers
This technology remains experimental and is not an established treatment. Access is limited to registered clinical studies.
Why this company matters
Gestala is China's counterpart to the ultrasound bet being made in the United States, and it raised RMB 570 million in its first six months on a similar premise: reading and writing brain activity through the skull. As of October 2026, everything public is a company statement. As with any pre-data company, its place on a maturity scale reflects capital and ambition, not evidence.
Key milestones
26 Aug 2026
Company says it will unveil a first-generation product and a brain foundation model by the end of 2026, before clinical trials.
Jul 2026
Angel+ round of RMB 420 million, with HSG, Lens Technology, Sinovation Ventures and C Capital joining, according to the company.
Mar 2026
Angel round of RMB 150 million, according to the company.
Funding history
- Jul 2026$62MAngel+Announced as RMB 420 million; the company gives about US$62 million.No lead investor is named.
- Mar 2026$22MAngelAnnounced as RMB 150 million. The company gives US$84 million for both rounds and about US$62 million for the second; the dollar figure here is the difference.Investors are those the company later called existing investors; no lead is named.
Investors namedHSG · Lens Technology · Sinovation Ventures · C Capital · Dalton Venture · Seas Capital · Tsing Song Capital · Gobi Partners
Rounds in the Briefing’s sample only; not a complete funding history.
Leadership
Phoenix Peng
Co-founder
Tianqiao Chen
Co-founder
As publicly stated by the organisation. Not a complete list.
Competitive context
Sources
- 01
China's BCI Race Accelerates: Gestala Raises US$84 Million in Six Months (opens in a new tab)
Company reportedGestala press release (PR Newswire)26 Aug 2026Checked against source 4 Oct 2026
Press release. States both rounds in RMB and the combined total in US dollars, and discloses no human or animal data.